Edesa Biotech

About Edesa Biotech

Edesa Biotech, Inc. is a clinical-stage biopharmaceutical company focused on developing novel treatments for inflammatory and immune-related diseases. Their goal is to transform the lives of patients suffering from acute and chronic conditions through innovative therapies.

Products & Services

Host Directed Therapeutics:Monoclonal antibody candidates developed as first-in-class treatments targeting immune dysregulation, with broad potential utility across multiple immune-related diseases.

Anti-Inflammatory Technology:Technology designed to modulate pathways implicated in inflammatory and immune-related conditions.

Specialties

Inflammatory Diseases Immune-Related Diseases Host-Directed Therapeutics Monoclonal Antibodies Acute Respiratory Distress Syndrome (ARDS)

Funding History

Debug: View Raw Funding Data

#	Type	Amount Fields	Date Fields	Investors
1	RT: Private Placement (Series B-1 Convertible Preferred Shares) T: - FT: Private Placement (Series B-1 Convertible Preferred Shares)	A: 15000000 MR: - FA: US$15,000,000 FAN: 15000000	D: 2025-02-13 FD: 2025-02-13	5 investors
2	RT: Private Placement T: - FT: Private Placement	A: 15000000 MR: - FA: $15.0 million FAN: 15000000	D: 2025-02-12 FD: 2025-02-12	6 investors
3	RT: Series A-1 Convertible Preferred T: - FT: Series A-1 Convertible Preferred	A: 5000000 MR: - FA: up to $5.0 million FAN: 5000000	D: 2024-10-31 FD: 2024-10-31	1 investors
4	RT: Grant T: - FT: Grant	A: 23000000 MR: - FA: 23 million FAN: 23000000	D: 2023-10-12 FD: 2023-10-12	1 investors
5	RT: Government Grant T: - FT: Government Grant	A: 23000000 MR: - FA: Up to C$23 million FAN: 23000000	D: 2023-10-12 FD: 2023-10-12	1 investors
6	RT: Debt T: - FT: Debt	A: 10000000 MR: - FA: 10 million FAN: 10000000	D: 2023-10-12 FD: 2023-10-12	1 investors

Private Placement (Series B-1 Convertible Preferred Shares) Latest

2025-02-13

$15.0M

5 investors (Pro only)

Private Placement 2025-02-12

$15.0M

Series A-1 Convertible Preferred 2024-10-31

$5.0M

View 5 more funding rounds with Pro

Unlock Full Funding History

Growth Metrics

+45%

Employee Growth

YoY

3.2x

Funding Growth

Last Round

12

Markets

Operating

10K+

Customers

Active

View 3 more growth metrics with Pro

Unlock All Metrics

Mock Up

Team & Leadership

P

Par Nijhawan

Chief Executive Officer

M

Michael Brooks

President

P

Peter J. Weiler

Chief Financial Officer

B

Blair Gordon

Vice President, Research and Development

G

Gary Koppenjan

Vice President, Corporate Affairs

View 2 more team members with Pro

Unlock Full Team Directory

Recent News

Edesa Biotech Announces New Product Launch

2 days ago

Company unveils innovative solution to transform the industry, expanding market reach and capabilities...

Leadership Team Expands with Industry Veteran

1 week ago

New executive brings 20+ years of experience to accelerate growth and strategic initiatives...

Company Recognized as Industry Leader

2 weeks ago

Receives prestigious award for innovation and customer satisfaction in competitive market...

Key Competitors

C1

Competitor Alpha

Series B · $50M raised

C2

Competitor Beta

Series C · $120M raised

C3

Competitor Gamma

Series A · $25M raised

C4

Competitor Delta

Seed · $10M raised